Starting doses and the monitoring that goes with them, for the medications geneticists are asked about most often. Open a card for the full dose sheet.
Respiratory and motor function, infusion-associated reactions and anti-drug antibodies per the centre protocol.
Cautions
Start treatment promptly in infantile-onset disease. Obtain CRIM status urgently and coordinate immune tolerance induction with the metabolic team for CRIM-negative infants around ERT initiation. Use product-specific premedication and monitoring, with personnel and equipment available to manage anaphylaxis. For weight-based orders, verify whether the label uses actual or adjusted body weight.
MetabolicUrea cycle substrate
Arginine
Urea cycle disorders, to restore the arginine-dependent steps of the cycle.
150 mg/kg over 24 hours as a continuous infusion; maximum 250 mg/kg per day. A loading dose is not needed for short-term emergency use.
Dosing
150 mg/kg over 24 hours as a continuous infusion; maximum 250 mg/kg per day. A loading dose is not needed for short-term emergency use.
Monitoring
Plasma ammonia, amino acids and electrolytes; follow with the specialist metabolic centre.
Cautions
Less urgent than the nitrogen scavengers in the emergency setting. Can be mixed with sodium benzoate and sodium phenylbutyrate in 10% glucose.
MetabolicUrea-cycle substrate
Arginine HCl IV
Urea-cycle disorders, to restore the arginine-dependent steps of the cycle.
Confirmed urea-cycle disorder: the cited label table lists 200 mg/kg for OTC/CPS1 and 600 mg/kg for ASS1/ASL, over 90-120 min, then the same dose over 24 hr.
Dosing
Confirmed urea-cycle disorder: the cited label table lists 200 mg/kg for OTC/CPS1 and 600 mg/kg for ASS1/ASL, over 90-120 min, then the same dose over 24 hr.
Monitoring
Plasma ammonia, amino acids and electrolytes; follow with the specialist metabolic centre.
Cautions
Avoid arginine in ARG1 deficiency. Confirm the dose and any maximum with the local pathway, especially in larger children or when the diagnosis is uncertain.
Urea cycle disorders - argininosuccinate synthetase (citrullinemia) and argininosuccinate lyase (ASA) deficiencies; part of acute hyperammonemia manag
IV, for suspected urea cycle disorder: 200-300 mg/kg (as a 6% solution) over 90 minutes, then 200-300 mg/kg/day by continuous infusion. Oral arginine base: 400-700 mg/kg/day divided 3-4 times daily, a
Dosing
IV, for suspected urea cycle disorder: 200-300 mg/kg (as a 6% solution) over 90 minutes, then 200-300 mg/kg/day by continuous infusion. Oral arginine base: 400-700 mg/kg/day divided 3-4 times daily, adjusted to plasma amino acids.
Monitoring
Plasma ammonia, plasma arginine and amino acids, and acid-base status.
Cautions
Disease-specific - use only the defect-appropriate substrate. The IV salt can cause hyperchloremic metabolic acidosis; watch for hyperargininemia.
MetabolicMedical formula
BCAA-free amino acid formula
Acute MSUD, to provide nitrogen and energy while branched-chain amino acids are withheld.
2-3.5 g/kg/day total protein equivalents in the cited inpatient regimen. Select the product, route and energy prescription with the metabolic dietitian.
Dosing
2-3.5 g/kg/day total protein equivalents in the cited inpatient regimen. Select the product, route and energy prescription with the metabolic dietitian.
Monitoring
Plasma branched-chain amino acids, glucose, sodium, osmolality and phosphorus.
Cautions
Give under metabolic dietitian supervision; adjust natural protein and reintroduce leucine as levels fall.
MetabolicWater-soluble vitamin
Biotin
Biotinidase deficiency (profound and partial).
Profound biotinidase deficiency: 5-10 mg PO daily as a fixed daily dose. Partial deficiency: GeneReviews lists 2.5-10 mg PO daily, with practice variation.
Dosing
Profound biotinidase deficiency: 5-10 mg PO daily as a fixed daily dose. Partial deficiency: GeneReviews lists 2.5-10 mg PO daily, with practice variation.
Monitoring
Serum biotinidase activity, with hearing and vision assessment.
Cautions
Use free biotin. Inform the laboratory of biotin use because it can interfere with some immunoassays.
MetabolicN-acetylglutamate analogue
Carglumic acid
Acute hyperammonaemia in NAGS deficiency and in propionic or methylmalonic acidaemia.
Acute NAGS deficiency: 100-250 mg/kg/day divided in 2-4 doses. Acute PA/MMA hyperammonaemia: 150 mg/kg/day if 15 kg or less; 3.3 g/m2/day if over 15 kg, given PO or enteral tube in 2 divided doses, co
Dosing
Acute NAGS deficiency: 100-250 mg/kg/day divided in 2-4 doses. Acute PA/MMA hyperammonaemia: 150 mg/kg/day if 15 kg or less; 3.3 g/m2/day if over 15 kg, given PO or enteral tube in 2 divided doses, continuing until ammonia is below 50 micromol/L for up to 7 days per label.
Monitoring
Plasma ammonia and clinical status.
Cautions
Disperse in water for PO or enteral tube use. Check renal adjustment in the label.
Intraventricular every 2 weeks via a surgically implanted reservoir, followed by the labelled intraventricular electrolyte solution: birth to under 6 months 100 mg; 6 months to under 1 year 150 mg; 1
Dosing
Intraventricular every 2 weeks via a surgically implanted reservoir, followed by the labelled intraventricular electrolyte solution: birth to under 6 months 100 mg; 6 months to under 1 year 150 mg; 1 year to under 2 years 200 mg for the first 4 doses then 300 mg; 2 years and older 300 mg.
Monitoring
CSF surveillance, device checks, seizure frequency and motor-language scores.
Cautions
The U.S. label advises against administration below 37 weeks postmenstrual age or below 2.5 kg. Follow device inspection, CSF surveillance and infusion-rate instructions in the product label.
Proximal urea cycle disorders - carbamoyl phosphate synthetase I (CPS1) and ornithine transcarbamylase (OTC) deficiency.
Oral or NG, 170 mg/kg/day divided 3-4 times daily, increasing to 350-400 mg/kg/day as needed. Adjust to plasma amino acids.
Dosing
Oral or NG, 170 mg/kg/day divided 3-4 times daily, increasing to 350-400 mg/kg/day as needed. Adjust to plasma amino acids.
Monitoring
Plasma citrulline, arginine and ammonia.
Cautions
Only for proximal urea cycle defects - arginine is preferred in argininosuccinate synthetase deficiency. Adjust with the metabolic team to avoid arginine depletion.
MetabolicCarbohydrate and energy substrate
Dextrose 10% (D10)
Hypoglycaemia and reversal of catabolism in a metabolic crisis.
10% dextrose 2 mL/kg IV for severe hypoglycaemia under the pediatric emergency protocol, followed by a glucose infusion or appropriate feeds. D10 at 4.8 mL/kg/hr delivers 8 mg/kg/min. Calculate the ac
Dosing
10% dextrose 2 mL/kg IV for severe hypoglycaemia under the pediatric emergency protocol, followed by a glucose infusion or appropriate feeds. D10 at 4.8 mL/kg/hr delivers 8 mg/kg/min. Calculate the actual GIR and adjust electrolytes and fluid volume for age, cardiac function and neurologic status.
Monitoring
Bedside glucose, GIR, electrolytes, osmolality and fluid balance.
Cautions
Concentrated dextrose needs central access. Watch for fluid overload and electrolyte disturbance; adjust volume and concentration to cardiac and renal status.
Urinary keratan sulfate, six-minute walk test and respiratory function.
Cautions
Use product-specific premedication and monitoring, with personnel and equipment available to manage anaphylaxis.
MetabolicRecombinant arylsulfatase B
Galsulfase (Naglazyme)
Mucopolysaccharidosis type VI (MPS VI).
1 mg/kg IV once weekly.
Dosing
1 mg/kg IV once weekly.
Monitoring
Urinary glycosaminoglycans, endurance and joint mobility.
Cautions
Use product-specific premedication and monitoring, with personnel and equipment available to manage anaphylaxis.
MetabolicVitamin B12 (cobalamin)
Hydroxocobalamin
Cobalamin-responsive methylmalonic acidaemia.
Suspected responsive methylmalonic acidaemia: 1 mg IM is a neonatal pathway initial dose. The stable-state responsiveness protocol uses 1 mg IM daily on 3 consecutive days with serial methylmalonate u
Dosing
Suspected responsive methylmalonic acidaemia: 1 mg IM is a neonatal pathway initial dose. The stable-state responsiveness protocol uses 1 mg IM daily on 3 consecutive days with serial methylmalonate under metabolic supervision.
Monitoring
Serial methylmalonate, plasma amino acids and total homocysteine.
Cautions
Obtain baseline specimens before cofactors if possible, and interpret responsiveness under metabolic supervision.
MetabolicRecombinant iduronate-2-sulfatase
Idursulfase (Elaprase)
Mucopolysaccharidosis type II (MPS II).
0.5 mg/kg IV once weekly.
Dosing
0.5 mg/kg IV once weekly.
Monitoring
Urinary glycosaminoglycans, six-minute walk test, respiratory and cardiac function.
Cautions
Infusion-associated reactions are common. Use product-specific premedication and monitoring, with personnel and equipment available to manage anaphylaxis.
MetabolicRecombinant acid beta-glucocerebrosidase
Imiglucerase (Cerezyme)
Gaucher disease types 1 and 3 (non-CNS manifestations).
2.5 units/kg IV three times weekly up to 60 units/kg IV every 2 weeks. Individualize by disease severity and treatment goals.
Dosing
2.5 units/kg IV three times weekly up to 60 units/kg IV every 2 weeks. Individualize by disease severity and treatment goals.
Monitoring
Haemoglobin, platelet count, spleen and liver volume, bone disease and biomarker response.
Cautions
Treats the non-CNS manifestations of Gaucher disease. Use product-specific premedication and monitoring, with personnel and equipment available to manage anaphylaxis. Verify the label's weight basis before ordering.
MetabolicBranched-chain amino acid
Isoleucine and valine
Acute MSUD, to replace the branched-chain amino acids that fall during treatment.
20-120 mg/kg/day each, enteral and/or parenteral under metabolic supervision, adjusted to measured amino acids and clinical response.
Dosing
20-120 mg/kg/day each, enteral and/or parenteral under metabolic supervision, adjusted to measured amino acids and clinical response.
Monitoring
Serial plasma branched-chain amino acids (leucine, isoleucine and valine) and clinical response.
Cautions
Use only under metabolic supervision; over-supplementation can raise the individual branched-chain amino acids.
MetabolicRecombinant alpha-L-iduronidase
Laronidase (Aldurazyme)
Mucopolysaccharidosis type I (MPS I).
0.58 mg/kg IV once weekly.
Dosing
0.58 mg/kg IV once weekly.
Monitoring
Urinary glycosaminoglycans, liver and spleen volume, respiratory function and joint mobility.
Cautions
Use product-specific premedication and monitoring, with personnel and equipment available to manage anaphylaxis. Verify the label's weight basis before ordering.
MetabolicCarnitine supplement
Levocarnitine
Secondary carnitine deficiency in fatty-acid oxidation defects such as MCAD deficiency, and in organic acidaemias.
Oral: 100 mg/kg per day in 3 to 4 divided doses, up to 200 mg/kg per day in severe deficiency. Intravenous: 50 mg/kg per dose during acute decompensation.
Dosing
Oral: 100 mg/kg per day in 3 to 4 divided doses, up to 200 mg/kg per day in severe deficiency. Intravenous: 50 mg/kg per dose during acute decompensation.
Monitoring
Plasma free carnitine, growth and feeding tolerance; review the emergency regimen at each visit.
Cautions
Can cause nausea, abdominal cramps and a fishy body odour. Give intravenously during acute illness when oral intake is unreliable.
Organic acidemias (methylmalonic and propionic acidemia) with secondary carnitine deficiency.
IV, during organic acidemia decompensation: 100 mg/kg/day as a continuous or divided infusion (up to 300-400 mg/kg/day in severe cases). Oral, 50-100 mg/kg/day divided 3-4 times daily.
Dosing
IV, during organic acidemia decompensation: 100 mg/kg/day as a continuous or divided infusion (up to 300-400 mg/kg/day in severe cases). Oral, 50-100 mg/kg/day divided 3-4 times daily.
Monitoring
Plasma ammonia, acylcarnitines, free and total carnitine, electrolytes.
Cautions
Use within the organic acidemia protocol. Watch for gastrointestinal upset and, rarely, seizures. Do not use for other causes of hyperammonemia without metabolic advice.
MetabolicCarnitine supplement
Levocarnitine (organic acidaemias)
Methylmalonic and propionic acidaemia, to restore carnitine and clear acyl-CoA esters.
Example neonatal emergency pathway: 50 mg/kg IV or enteral loading, then 100 mg/kg/day IV or enteral, continuous or divided every 6-8 hr. Confirm with the metabolic team.
Dosing
Example neonatal emergency pathway: 50 mg/kg IV or enteral loading, then 100 mg/kg/day IV or enteral, continuous or divided every 6-8 hr. Confirm with the metabolic team.
Monitoring
Plasma carnitine, ammonia, blood gas, electrolytes, glucose and urine output.
Cautions
Confirm the route and dose with the metabolic team. High enteral doses can cause diarrhoea or a fishy body odour.
MetabolicCarnitine supplement
Levocarnitine (primary carnitine deficiency)
Primary carnitine deficiency.
Chronic targeted treatment: 100-200 mg/kg/day PO in 3 doses, titrated to plasma carnitine.
Dosing
Chronic targeted treatment: 100-200 mg/kg/day PO in 3 doses, titrated to plasma carnitine.
Monitoring
Plasma free and total carnitine; cardiac function where cardiomyopathy is suspected.
Cautions
Acute illness also requires prompt carbohydrate support. Evaluate maternal carnitine when a low C0 newborn screen raises concern.
Metabolic4-HPPD inhibitor
Nitisinone
Tyrosinemia type I (FAH deficiency).
Starting dose 0.5 mg/kg/dose PO twice daily. Titrate with the specialist per label, up to 2 mg/kg/day.
Dosing
Starting dose 0.5 mg/kg/dose PO twice daily. Titrate with the specialist per label, up to 2 mg/kg/day.
Monitoring
Succinylacetone, amino acids, AFP, liver imaging and drug levels according to the centre protocol.
Cautions
Pair with a tyrosine- and phenylalanine-restricted diet.
MetabolicRecombinant acid sphingomyelinase
Olipudase alfa (Xenpozyme)
Acid sphingomyelinase deficiency (ASMD) in patients aged 0-17 years.
For non-CNS manifestations, IV every 2 weeks with stepwise escalation in mg/kg: week 0 0.03, week 2 0.1, weeks 4 and 6 0.3, weeks 8 and 10 0.6, week 12 1, week 14 2, week 16 3. Continue 3 mg/kg IV eve
Dosing
For non-CNS manifestations, IV every 2 weeks with stepwise escalation in mg/kg: week 0 0.03, week 2 0.1, weeks 4 and 6 0.3, weeks 8 and 10 0.6, week 12 1, week 14 2, week 16 3. Continue 3 mg/kg IV every 2 weeks after the first 3 mg/kg dose.
Monitoring
ALT, AST, spleen and liver volume, lung function and infusion-associated reactions.
Cautions
Check ALT and AST per label before initiation and during escalation. Use actual body weight when BMI is 30 kg/m² or less; for BMI above 30 kg/m² the label uses adjusted weight in kg = 30 x height in metres squared. Follow the label's restart schedule after missed doses.
Phenylketonuria (PKU) in patients aged 12 years or older with blood phenylalanine above 600 micromol/L despite existing management.
Subcutaneous. Induction: 2.5 mg once weekly for 4 weeks. Titration: if tolerated, at least 1 week per step - 2.5 mg twice weekly, 10 mg once weekly, 10 mg twice weekly, 10 mg four times weekly, then 1
Dosing
Subcutaneous. Induction: 2.5 mg once weekly for 4 weeks. Titration: if tolerated, at least 1 week per step - 2.5 mg twice weekly, 10 mg once weekly, 10 mg twice weekly, 10 mg four times weekly, then 10 mg daily. Maintenance: start 20 mg daily; if control is inadequate after at least 24 continuous weeks consider 40 mg daily; if still inadequate after at least 16 continuous weeks at 40 mg consider 60 mg daily (maximum). Discontinue if the response remains inadequate after 16 continuous weeks at 60 mg daily.
Monitoring
Blood phenylalanine at baseline and during treatment; hypersensitivity and anaphylaxis.
Cautions
Prescribe epinephrine before the first dose and observe for at least 60 minutes after the supervised initial administration. The U.S. label requires a REMS programme because of anaphylaxis risk.
MetabolicSynthetic tetrahydrobiopterin cofactor
Sapropterin
BH4-responsive phenylketonuria, used alongside a phenylalanine-restricted diet to lower blood phenylalanine.
20 mg/kg orally once daily for the initial 4-week responsiveness trial. Maintenance 5 to 20 mg/kg once daily, guided by phenylalanine response.
Dosing
20 mg/kg orally once daily for the initial 4-week responsiveness trial. Maintenance 5 to 20 mg/kg once daily, guided by phenylalanine response.
Monitoring
Blood phenylalanine at baseline, weekly during the trial and then regularly; review dietary phenylalanine intake as levels fall.
Cautions
Can cause a rapid fall in phenylalanine with associated neurological change if the diet is not adjusted. Review interactions with folate metabolism and monitor for hypersensitivity.
MetabolicRecombinant lysosomal acid lipase
Sebelipase alfa (Kanuma)
Lysosomal acid lipase (LAL) deficiency.
Rapidly progressive disease presenting in the first 6 months of life: 1 mg/kg IV once weekly, increasing to 3 mg/kg weekly and then 5 mg/kg weekly if the response is suboptimal. Other pediatric patien
Dosing
Rapidly progressive disease presenting in the first 6 months of life: 1 mg/kg IV once weekly, increasing to 3 mg/kg weekly and then 5 mg/kg weekly if the response is suboptimal. Other pediatric patients: 1 mg/kg IV every 2 weeks, increasing to 3 mg/kg every 2 weeks if the response is suboptimal.
Monitoring
ALT, AST, lipid profile, liver volume and growth.
Cautions
Use product-specific premedication and monitoring, with personnel and equipment available to manage anaphylaxis. Escalate the dose according to the response.
MetabolicNitrogen scavenger (conjugates glycine to hippurate)
Sodium benzoate
Hyperammonemia in urea cycle disorders; given enterally for maintenance and intravenously with sodium phenylacetate for acute episodes.
Oral or NG, 250 mg/kg/day divided every 6 hours. IV (combined with sodium phenylacetate as Ammonul): 250 mg/kg loading dose over 90-120 minutes, then 250 mg/kg/day by continuous infusion.
Dosing
Oral or NG, 250 mg/kg/day divided every 6 hours. IV (combined with sodium phenylacetate as Ammonul): 250 mg/kg loading dose over 90-120 minutes, then 250 mg/kg/day by continuous infusion.
Monitoring
Plasma ammonia, electrolytes, acid-base status and fluid balance.
Cautions
Sodium load and risk of hypernatremia. May cause nausea and vomiting. Give with fluid and amino acid support and only within the metabolic team's emergency protocol.
MetabolicNitrogen scavenger
Sodium benzoate
Urea cycle disorders, as part of nitrogen-scavenger therapy for hyperammonaemia.
250 to 500 mg/kg per day by mouth or infusion, combined with sodium phenylbutyrate as directed by metabolic medicine.
Dosing
250 to 500 mg/kg per day by mouth or infusion, combined with sodium phenylbutyrate as directed by metabolic medicine.
Monitoring
Plasma ammonia, blood gases, sodium and potassium, and acid-base status.
Cautions
Use with care alongside glycine; monitor for metabolic acidosis and electrolyte shifts.
MetabolicNitrogen scavenger
Sodium benzoate
Hyperammonaemia in urea cycle disorders (OTC and CPS deficiencies), to remove nitrogen by an alternative pathway.
Emergency: 250 mg/kg loading dose over 90 minutes, then 250 mg/kg over 24 hours as a continuous infusion; maximum 500 mg/kg per day.
Dosing
Emergency: 250 mg/kg loading dose over 90 minutes, then 250 mg/kg over 24 hours as a continuous infusion; maximum 500 mg/kg per day.
Monitoring
Plasma ammonia, blood gases, urea and electrolytes, glucose and sodium; reassess every 4-6 hours until stable.
Cautions
The daily maintenance dose carries about 3.5 mmol/kg/day of sodium. Give as a continuous infusion and do not delay starting in acute decompensation.
MetabolicNitrogen scavenger
Sodium phenylacetate + sodium benzoate IV
Hyperammonaemia in urea-cycle disorders (OTC, CPS1, NAGS, ASS1 and ASL deficiencies).
Each component: 250 mg/kg if 20 kg or less; 5.5 g/m2 if over 20 kg. Give the loading dose over 90-120 min, then the same amount of each over 24 hr. Dilute in D10 and use central access per label.
Dosing
Each component: 250 mg/kg if 20 kg or less; 5.5 g/m2 if over 20 kg. Give the loading dose over 90-120 min, then the same amount of each over 24 hr. Dilute in D10 and use central access per label.
Monitoring
Ammonia every 1-2 hours early in a severe crisis, mental status, glucose, sodium, potassium and acid-base status.
Cautions
Verify the sodium load and avoid repeat loading. Reconcile existing nitrogen scavengers before starting acute IV treatment.
MetabolicNitrogen scavenger
Sodium phenylbutyrate
Hyperammonaemia in urea cycle disorders (OTC and CPS deficiencies).
Emergency: 250 mg/kg loading dose over 90 minutes, then 250 mg/kg over 24 hours as a continuous infusion; maximum 500 mg/kg per day.
Dosing
Emergency: 250 mg/kg loading dose over 90 minutes, then 250 mg/kg over 24 hours as a continuous infusion; maximum 500 mg/kg per day.
Monitoring
Plasma ammonia, blood gases, urea and electrolytes and acid-base status every 4-6 hours until stable.
Cautions
Sodium load of about 2.8 mmol/kg/day in the daily maintenance dose. May be mixed with sodium benzoate and L-arginine in 10% glucose (maximum 2.5 g of each in 50 ml). Outside the UK, Ammonul combines phenylbutyrate/phenylacetate with sodium benzoate.
MetabolicNitrogen scavenger
Sodium phenylbutyrate
Urea cycle disorders, to control hyperammonaemia alongside dietary protein restriction.
450 to 600 mg/kg per day by mouth or infusion, in 3 to 4 divided doses, adjusted to plasma ammonia and amino acids.
Dosing
450 to 600 mg/kg per day by mouth or infusion, in 3 to 4 divided doses, adjusted to plasma ammonia and amino acids.
Chronic maintenance of urea cycle disorders once acute hyperammonemia is under control; adjunct nitrogen-scavenger therapy.
Oral or NG, divided 4-6 times daily with feeds. Neonates and infants: up to 450-600 mg/kg/day (maximum 11.9 g/m2/day). Older children: 450-600 mg/kg/day (maximum 19.8 g/day). Titrate to plasma ammonia
Dosing
Oral or NG, divided 4-6 times daily with feeds. Neonates and infants: up to 450-600 mg/kg/day (maximum 11.9 g/m2/day). Older children: 450-600 mg/kg/day (maximum 19.8 g/day). Titrate to plasma ammonia and glutamine.
Monitoring
Plasma ammonia and glutamine, amino acids, electrolytes, acid-base status, albumin, growth and neurologic status.
Cautions
High sodium load. Can cause metabolic acidosis, hypokalemia and hypoalbuminemia. Do not rely on it alone in acute severe decompensation - combine with IV nitrogen scavengers and dextrose.
Neurologic manifestations of mucopolysaccharidosis II (Hunter syndrome) in pediatric patients.
IV weekly escalation: 3 mg/kg for at least 4 weeks, then 7.5 mg/kg for at least 4 weeks, then 15 mg/kg weekly as maintenance if tolerated. Follow the label for transition from idursulfase.
Dosing
IV weekly escalation: 3 mg/kg for at least 4 weeks, then 7.5 mg/kg for at least 4 weeks, then 15 mg/kg weekly as maintenance if tolerated. Follow the label for transition from idursulfase.
Monitoring
CSF heparan sulfate and neurologic function; infusion-associated reactions.
Cautions
Accelerated approval was based on a reduction in CSF heparan sulfate; confirmatory evidence of clinical benefit is required. Start in patients weighing at least 5 kg before advanced neurologic impairment, and follow the label for infusion-reaction precautions and monitoring.
Infusion-associated reactions; clinical response and urinary GAGs as directed.
Cautions
Use product-specific premedication and monitoring, with personnel and equipment available to manage anaphylaxis. Confirm the current SFDA-approved product information and hospital pharmacy protocol before prescribing.